The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,959.00
Bid: 1,952.00
Ask: 1,954.00
Change: 20.00 (1.03%)
Spread: 2.00 (0.102%)
Open: 1,940.00
High: 1,971.00
Low: 1,940.00
Prev. Close: 1,939.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Thursday broker round-up UPDATE

Thu, 28th Feb 2013 07:19

AZ Electronic Materials: Goldman Sachs moves target price from 440p to 450p and retains a buy recommendation.Bovis Homes Group: Deutsche Bank shifts target price from 667p to 679p, while downgrading to hold.British American Tabacco: Investec places its target price (previously 3350p) and buy recommendation under review.Croda International: Goldman Sachs raises target price from 3150p to 3200p still recommending strong buying.Elementis: Goldman Sachs revises target price from 255p to 265p, while its neutral rating remains unchanged.Eurasian Natural Resources: Deutsche Bank lowers target price from 562p to 550p and stays with its buy recommendation.Genel Energy: Investec reduces target price from 1104p to 1000p keeping its buy recommendation.Gooch & Housego: N+1 Singer raises target price from 470p to 515p and upgrades to buy.Hays: Jefferies takes target price from 105p to 115p and reiterates its buy recommendation.Henderson Group: Morgan Stanley cuts target price from 160p to 154p, while retaining an equal-weight rating. UBS downgrades to neutral with a target price of 158p. Barclays lowers target price from 153p to 145p and reiterates an underweight rating. JP Morgan raises target price from 162p to 183p and maintains its neutral rating.Hikma: Panmure Gordon raises target price from 825p to 930p, while staying with its buy recommendation.Interserve: JP Morgan increases target price from 466p to 532p reiterating an overweight rating.Intu Properties: Jefferies lowers target price from 335p to 310p maintaining a hold recommendation. Deutsche Bank reduces target price from 480p to 410p and keeps its buy rating.ITV: Deutsche Bank ups target price from 90p to 100p, but still recommends selling. UBS raises target price from 90p to 115p and retains an equal-weight rating. Westhouse Securities increases target price from 133p to 141p and upgrades from add to buy. Investec shifts target price from 100p to 110p and upgrades from sell to hold. JP Morgan shifts target price from 120p to 126p, while its neutral rating remains unchanged. Panmure Gordon ups target price from 140p to 180p leaving its buy recommendation unaltered.LSL Property Services: Panmure Gordon ups target price from 287p to 337p and retains a buy recommendation.Petrofac: Morgan Stanley reduces target price from 2300p to 2100p, while leaving its overweight rating unchanged. Nomura downgrades target price from 1830p to 1740p reiterating a buy recommendation. Barclays cuts target price from 1900p to 1800p and reiterates an underweight rating.Promethean: JP Morgan shifts target price from 20p to 22p and leaves its neutral rating unchanged.Restaurant Group: Barclays takes target price from 400p to 460p, while staying with its overweight rating.Segro: Jefferies moves target price from 228p to 238p and keeps a hold recommendation.Severfield-Rowen: Canaccord Genuity reduces target price from 50p to 37p, while its sell recommendation is kept.Shire: Nomura cuts target price from 2300p to 2160p and downgrades from buy to neutral.Spirent Communications: Canaccord Genuity reduces target price from 180p to 156p downgrading from buy to hold. Panmure Gordon shifts target price from 192p to 191p and reiterates a buy recommendation.Standard Life: Credit Suisse shifts target price from 315p to 321p and keeps its underperform rating.St. James's Place: Investec places its target price (previously 472p) and buy recommendation under review.Synthomer: Goldman Sachs raises target price from 195p to 230p, while maintaining a neutral rating.United Carpets: After having had its target price under review, Cantor Fitzgerald places it at 2.5p and retains a hold recommendation.Victrex: Goldman Sachs increases target price from 1775p to 1850p reiterating a buy rating.Vitec Group: Investec moves target price from 700p to 740p and retains a buy recommendation.Weir Group: JP Morgan raises target price from 2500p to 2600p, while its overweight rating remains unchanged.Whitbread: Nomura ups target price from 2650p to 2968p and leaves its buy recommendation unaltered.Xchanging: Cantor Fitzgerald raises target price from 120p to 145p upgrading from hold to buy.
More News
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more
3 Nov 2022 11:08

With tighter purse strings, is parity less probable for the pound?

STOXX 600 down 1.1%

*

Read more
3 Nov 2022 09:28

Banks, insurance dodge carnage as real estate stocks sink

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.